title: [Treatment of anterior segment fibrinous reactions and hemorrhage with intracameral low dose rt-PA: clinical study and review of the literature].
abstract: OBJECTIVE
  to evaluate the efficacy and the safety of low dose intraocular tissue plasminogen activator (rt-PA) in the treatment of traumatic hyphema and postoperative fibrinous membrane.
  
  
  METHODS
  Six microg to 10 microg of rt-PA was injected into the anterior chamber to treat severe fibrinous postoperative membranes and total traumatic hyphemae.
  
  
  RESULTS
  Thirteen eyes of 13 patients were treated. Four cases of traumatic hyphema and 9 cases of fibrinous membranes were included. Complete fibrinolysis within 24 hours was observed in 4 cases (30.8%). A partial success was noted in 7 eyes (53.8%). No beneficial effect was observed in two cases of traumatic hyphema associated with intravitreal hemorrhage after penetrating trauma. No side effect attributable to rt-PA occurred.
  
  
  CONCLUSIONS
  Low dose intraocular rt-PA appears to be safe and effective in the treatment of postoperative fibrinous membrane and endocular hemorrhage limited to the anterior chamber.
authors.affiliation: Service d'ophtalmologie Hôtel-Dieu de Paris.
authors.forename: J F
authors.initials: JF
authors.lastname: Le Rouic
authors.forename: F
authors.initials: F
authors.lastname: Behar-Cohen
authors.forename: M H
authors.initials: MH
authors.lastname: Nghiem
authors.forename: G
authors.initials: G
authors.lastname: Renard
authors.forename: D
authors.initials: D
authors.lastname: Chauvaud
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005131:Eye Injuries / Q000188:drug therapy*; D005260:Female; D005337:Fibrin / Q000378:metabolism*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D006988:Hyphema / Q000188:drug therapy*; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures; D011183:Postoperative Complications / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005337:Fibrin; D010959:Tissue Plasminogen Activator